Sign in Subscribe
Drugs

Viventia Biotech Receives Clearance for Proxinium Phase 2 Study

Strategic Insights

— 1 min read

Viventia Biotech Inc. has received clearance from Health Canada to initiate a phase 2 study evaluating Proxinium for the treatment of patients with chemotherapy-refractory recurrent head and neck cancer. Following the FDA's clearance in October 2005, the company is set to initiate the trial by the end of the year. Proxinium, a novel cancer treatment, combines a potent cytotoxic protein payload with the precise tumour-targeting capabilities of a monoclonal antibody. This targeted approach aims to deliver the payload directly to the tumour, reducing harm to healthy cells.

Key Takeaways:

  • Viventia Biotech Inc. has received clearance from Health Canada to initiate a phase 2 study evaluating Proxinium for chemotherapy-refractory recurrent head and neck cancer.
  • Proxinium combines a powerful cytotoxic protein payload with the highly precise tumour-targeting characteristics of a monoclonal antibody.
  • A single molecule of the cytotoxic protein payload, Pseudomonas exotoxin, is capable of killing a cancer cell.
  • The antibody fragment of Proxinium targets EpCAM, an antigen that is highly expressed on many epithelial cancers including head and neck cancer.
  • Proxinium has been designated an orphan drug for the treatment of head and neck cancer in the U.S. and EU.
  • Head and neck cancer is the ninth most common cancer in North America, with approximately 55,000 new cases diagnosed annually in the U.S. alone, leading to 14,000 deaths annually.
  • Recurrence rates for head and neck cancer are high, with 60-70% of patients experiencing a relapse.

Statistics:

  • 55,000 new cases of head and neck cancer diagnosed annually in the U.S. alone.
  • 14,000 deaths annually from head and neck cancer in North America.
  • 60-70% of head and neck cancer patients experience recurrence.
  • Proxinium has been designated an orphan drug for head and neck cancer treatment in the U.S. and EU.

Sources:

  • Health & Medicine Week, "Viventia Biotech Inc. Receives Clearance for Phase 2 Study of Proxinium," October 2005, Health & Medicine Week editors from staff and other reports, Copyright 2005, Health & Medicine Week via NewsRx.com.

Read more